433 related articles for article (PubMed ID: 24297687)
1. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
2. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.
Allen LA; Shetterly SM; Peterson PN; Gurwitz JH; Smith DH; Brand DW; Fairclough DL; Rumsfeld JS; Masoudi FA; Magid DJ
Circ Heart Fail; 2014 Jan; 7(1):43-50. PubMed ID: 24281136
[TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
[TBL] [Abstract][Full Text] [Related]
6. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
Secora AM; Shin JI; Qiao Y; Alexander GC; Chang AR; Inker LA; Coresh J; Grams ME
Mayo Clin Proc; 2020 Nov; 95(11):2408-2419. PubMed ID: 33153631
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Filippatos G; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Kim SY; Nowack C; Palombo G; Kolkhof P; Kimmeskamp-Kirschbaum N; Pieper A; Pitt B
Eur Heart J; 2016 Jul; 37(27):2105-14. PubMed ID: 27130705
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.
Cooper LB; Hammill BG; Peterson ED; Pitt B; Maciejewski ML; Curtis LH; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28073850
[TBL] [Abstract][Full Text] [Related]
9. A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
Ahmed A; Pitt B
Am J Cardiol; 2009 May; 103(10):1374-80. PubMed ID: 19427431
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
Wang TY; Vora AN; Peng SA; Fonarow GC; Das S; de Lemos JA; Peterson ED
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796254
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
12. Timing of Worsening Renal Function in Patients Hospitalized for Heart Failure Exacerbation Who Were Being Treated With Intravenous Diuretic Therapy.
Shiraishi Y; Kurita Y; Mori H; Oishi K; Matsukawa M
Circ J; 2024 Apr; 88(5):680-691. PubMed ID: 38143082
[TBL] [Abstract][Full Text] [Related]
13. Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.
Medeiros M; Velásquez-Jones L; Hernández AM; Ramón-García G; Valverde S; Fuentes Y; Vargas A; Patiño M; Pérez-Villalva R; Ortega-Trejo JA; Barrera-Chimal J; Bobadilla NA
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1291-1300. PubMed ID: 28536123
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eplerenone in heart failure management.
Zheng J; Wang S; Timóteo AT
Eur J Intern Med; 2024 May; 123():163-164. PubMed ID: 38365517
[No Abstract] [Full Text] [Related]
15. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function.
Matsumoto S; Henderson AD; Shen L; Yang M; Swedberg K; Vaduganathan M; van Veldhuisen DJ; Solomon SD; Pitt B; Zannad F; Jhund PS; McMurray JJV
J Am Coll Cardiol; 2024 May; ():. PubMed ID: 38739064
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Pitt B; Bakris GL; Weir MR; Freeman MW; Lainscak M; Mayo MR; Garza D; Zawadzki R; Berman L; Bushinsky DA
ESC Heart Fail; 2018 Aug; 5(4):592-602. PubMed ID: 29767459
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study.
Nash DM; Markle-Reid M; Brimble KS; McArthur E; Roshanov PS; Fink JC; Weir MA; Garg AX
Nephrol Dial Transplant; 2019 Jul; 34(7):1145-1154. PubMed ID: 31264694
[TBL] [Abstract][Full Text] [Related]
18. Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes.
Dey S; Garg J; Wang A; Holzner E; Frishman WH; Aronow WS
Cardiol Rev; 2024 May-Jun 01; 32(3):285-288. PubMed ID: 36946916
[TBL] [Abstract][Full Text] [Related]
19. Implications of worsening renal function before hospitalization for acute heart failure.
Wettersten N; Duff S; Horiuchi Y; van Veldhuisen DJ; Mueller C; Filippatos G; Nowak R; Hogan C; Kontos MC; Cannon CM; Müeller GA; Birkhahn R; Taub P; Vilke GM; McDonald K; Mahon N; Nuñez J; Briguori C; Passino C; Maisel A; Murray PT; Ix JH
ESC Heart Fail; 2023 Feb; 10(1):532-541. PubMed ID: 36325747
[TBL] [Abstract][Full Text] [Related]
20. The role of patiromer: Comparing OPAL-HK data with untreated real-world patients in the United Kingdom-A retrospective, propensity-matched analysis.
Ali I; Chinnadurai R; Cornea G; Intorcia M; Kalra PA
PLoS One; 2020; 15(8):e0237467. PubMed ID: 32853209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
